Medications that act on incretin receptors are booming for treating type 2 diabetes and helping with weight loss. One of them is tirzepatide, sold as Mounjaro®, which works on two receptors (GLP-1 and GIP), increasing satiety, reducing appetite, and controlling blood sugar levels (AGENCY…, 2025). But while it helps during use, what happens after you stop taking it? Tirzepatide takes about five days to leave the body, so around three to four weeks after the last dose, it is completely gone (FELLA…, 2025). At that point, the changes it caused in the body begin to reverse. Appetite and satiety return to previous levels, and many people start feeling hungrier within…

Living longer is not just about adding years, but about having a good life, with a well-functioning body and a healthy mind, even as age advances. Several studies have shown that people who take care of their health live longer and are less likely to develop chronic diseases, regardless of their genetic background. One key factor for a healthy life is staying physically active. People who engage in moderate or vigorous physical activity have a lower risk of death from any cause, including cardiovascular problems. A study conducted in China showed that older adults who remain active significantly reduce their risk of mortality, even when they already have other health…

Obesity has become a chronic and serious problem that increases the risk of heart disease, type 2 diabetes, high cholesterol, and can shorten life expectancy. Since controlling weight through diet and exercise alone is often difficult, doctors have increasingly turned to medications. That’s where Mounjaro comes in—a relatively new drug for type 2 diabetes that has also been helping people lose weight. But hold on—let’s take a closer look at its benefits, risks, and what is often left unsaid. Mounjaro works on two hormones at the same time: GLP-1 and GIP. This action increases insulin release when needed, reduces glucagon production, slows gastric emptying, and enhances the feeling of fullness.…

Currently, obesity and overweight represent major public health concerns, as they significantly increase the risk of cardiovascular diseases, type 2 diabetes, and other metabolic disorders. Consequently, new pharmacological strategies have been developed to support weight reduction in individuals with excess body weight. Among these therapies, tirzepatide, marketed as Mounjaro® for the treatment of type 2 diabetes, has demonstrated considerable potential for weight loss, including its use as an injectable therapy for obesity, either off-label or under expanded clinical indications (BEZERRA, 2025, p. 1). Tirzepatide acts as a dual agonist of the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. This dual mechanism promotes glucose-dependent insulin secretion, suppresses…